Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
<h4>Background</h4>Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy.<h4>Methods and findings</h4>14 subjects with...
Guardado en:
Autores principales: | Daniel A Monti, Edith Mitchell, Anthony J Bazzan, Susan Littman, George Zabrecky, Charles J Yeo, Madhaven V Pillai, Andrew B Newberg, Sandeep Deshmukh, Mark Levine |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/09b8615a61a7470da45dce0f0c6aad39 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Erlotinib in the treatment of advanced pancreatic cancer
por: Robin K Kelley, et al.
Publicado: (2008) -
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
por: Jasmine G Lee, et al.
Publicado: (2012) -
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong DJ, et al.
Publicado: (2013) -
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo ZY, et al.
Publicado: (2018) -
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Ru Chen, et al.
Publicado: (2017)